Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritonavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 known ✓ | P08684 | 20/20 | 1.00 |
| ▸ | CYP3A5 known ✓ | P20815 | 1/20 | 1.00 |
| ▸ | CYP3A7 known ✓ | P24462 | 1/20 | 1.00 |
| ▸ | CYP3A43 known ✓ | Q9HB55 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritonavir SCHEMBL7806137 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL1560720 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL825767 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL12175481 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL24777041 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL20322359 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL23927481 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL6679 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL17787453 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL20257193 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493425-A | Preparation method of ritonavir | 北京万全德众医药生物技术有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-101361723-A | Improved pharmaceutical compositions | ABBOTT LAB (US) | 2009-02-11 | — | — | CN | claimed |
| CN-100418527-C | Improved pharmaceutical formulations | ABBOTT LAB (US) | 2008-09-17 | — | — | CN | claimed |
| EP-4577541-A2 | PROCESS FOR PREPARING FORM III OF RITONAVIR | Varda Space Industries, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12318370-B2 | Processes for preparing solid state forms | VARDA SPACE INDUSTRIES, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240269118-A1 | PROCESSES FOR PREPARING SOLID STATE FORMS | VARDA SPACE INDUSTRIES, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-118103044-A | Use of ritonavir for treating SARS-CoV-2 infection | 中国人民解放军军事科学院军事医学研究院 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024050019-A2 | PROCESSES FOR PREPARING SOLID STATE FORMS | VARDA SPACE INDUSTRIES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240041828-A1 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | disclosed |
| US-20230270677-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2023-08-31 | — | — | US | disclosed |
| US-20070031408-A1 | Anti-CCR5 antibody | PROGENICS PHARMACEUTICALS INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032435-A1 | Pharmaceutical formulations | ABBOTT LABORATORIES | 2007-02-08 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| WO-2007002411-A1 | ANTIVIRAL COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2005111006-A1 | RITONAVIR ANALOGOUS COMPOUND USEFUL AS RETROVIRAL PROTEASE INHIBITOR, PREPARATION OF THE RITONAVIR ANALOGOUS COMPOUND AND PHARMACEUTICAL COMPOSITION FOR THE RITONAVIR ANALOGOUS COMPOUND. | Cristália Produtos Químicos Farmacêuticos Ltda. (BR) | 2005-11-24 | — | — | WO | disclosed |
| CN-1621418-A | Recombinant targeted toxin against HIV-1 | MILITARY VETERINARY INST QUART (CN) | 2005-06-01 | — | — | CN | disclosed |
| US-20040197321-A1 | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients | DIGESTIE CARE INC. | 2004-10-07 | — | — | US | disclosed |
| US-5948786-A | BLOCKING TUMOR NECROSIS FACTOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032435-A1 | Pharmaceutical formulations | TMPRSS15, PRSS3, PRSS8 | CYP3A4 201/4885CYP3A5 156/4885CYP3A7 147/4885 |
| US-20070009593-A1 | Methods of treating cancer | CAPN2, CAPN9, CAPN1 | CYP3A4 2906/4885CYP3A5 1936/4885CYP3A7 1838/4885 |
| US-12318370-B2 | Processes for preparing solid state forms | CYP3A4, CYP3A43, CYP3A5 | CYP3A4 1/4885CYP3A5 3/4885CYP3A7 5/4885 |
| US-20240269118-A1 | PROCESSES FOR PREPARING SOLID STATE FORMS | CYP3A4, CYP3A43, CYP3A5 | CYP3A4 1/4885CYP3A5 3/4885CYP3A7 5/4885 |
| US-20040197321-A1 | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients | PNLIP, RNASE1, LIPC | CYP3A4 1150/4885CYP3A5 638/4885CYP3A7 574/4885 |
| US-20240041828-A1 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | KEAP1, HMOX1, NFE2L2 | CYP3A4 785/4885CYP3A5 1431/4885CYP3A7 1344/4885 |
| US-20230270677-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | VEGFA, ADAR, EIF2AK2 | CYP3A4 2418/4885CYP3A5 1737/4885CYP3A7 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.